July 27 – 31 | Chicago, IL
Get Ready for ADLM 2025!
Join us at Booth #2803
Did you know that Cepheid is a part of Danaher's diagnostic companies?
Together with Danaher's diagnostics businesses, we are accelerating the real-life impact of diagnostics, aiding healthcare providers in diagnosing diseases with unprecedented speed and precision.
Join us to explore our cutting-edge diagnostic tools and attend insightful presentations.
Stronger Together: Advancing Infectious Disease Diagnostics in Acute Care
Tuesday, July 29 | 11:00 a.m. | Booth #2803
Dr. Cristina Baker, Senior Director Medical Affairs, Cepheid
Dr. Stephanie Mitchell, Senior Director, Scientific Affairs, Beckman Coulter Microbiology
Dr. Kasper Andersen, Senior Medical Advisor, Radiometer
Dr. Melissa Naiman, Medical Director, Beckman Coulter
Laboratorians increasingly provide the critical diagnostic data that guides treatment decisions and precision medicine. Finding the right diagnostic solution partner can further elevate laboratory leadership through clinical, technological, and operational innovation. This session explores how the cross-disciplinary implementation of novel biomarkers, high resolution instruments, and AI-driven clinical decision support empowers lab teams to better partner with providers managing complex acute infectious disease.
Bottoms Up: Tackling Clostridioides difficile and Gram-Negative Resistance at the Source
Tuesday, July 29 | 12:00 p.m. | Booth #2803
Nick Moore, Ph.D, D(ABMM), MLS(ASCP)CM
Associate Director of Clinical Microbiology
& Associate Professor
Rush University Medical Center
This presentation will highlight the utility of testing to directly detect Clostridioides difficile and antimicrobial resistance gene targets in Gram-negative bacilli. This approach enables real-time epidemiologic surveillance for critical HAI pathogens and supports targeted treatment decisions based on the antimicrobial resistance mechanisms identified.
Emerging and Evolving Respiratory Viruses: Test Design Matters!
Tuesday, July 29 | 4:00 p.m. | Booth #2803
Mike Loeffelholz, Ph.D, D(ABMM)
Vice President, Scientific Affairs
Cepheid
Respiratory viruses, including influenza viruses, RSV and SARS-CoV-2 (the virus that causes COVID-19) continue to cause significant morbidity, mortality, and economic burden. Accurate and quick diagnosis in the laboratory or at the point of care is important to effectively manage infections, drive appropriate use of antiviral treatment, and reduce disease transmission. These viruses change over time, driving the emergence of new strains and variants that can challenge the performance of diagnostic tests. It is crucial that these tests are designed with the robustness to detect newly emerging strains of respiratory viruses.
Date
07/29/25
Cepheid Booth #2803
Time
11:00 AM
Stronger Together: Advancing Infectious Disease Diagnostics in Acute Care
12:00 PM
Bottoms Up: Tackling Clostridioides difficile and Gram-Negative Resistance at the Source
4:00 PM
Emerging and Evolving Respiratory Viruses: Test Design Matters!
Join us at ADLM!
Fill out the form below to speak with a sales rep and schedule a booth tour!
About Cepheid
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most from central laboratories and hospitals to near patient settings.
For more information, visit www.cepheid.com
904 Caribbean Drive, Sunnyvale, CA 94089
©2026 Cepheid. All Rights Reserved.